Literature DB >> 22067483

The ubiquitin hydrolase USP22 contributes to 3'-end processing of JAK-STAT-inducible genes.

Edmond Chipumuro1, Melissa A Henriksen.   

Abstract

The JAK-STAT (Janus kinase-signal transducer and activator of transcription) signaling pathway drives cellular growth, differentiation, and the immune response. STAT-activated gene expression is both rapid and transient and requires dynamic post-translational modification of the chromatin template. We previously showed that monoubiquitination of histone H2B (ubH2B) is highly dynamic at the STAT1 target gene, interferon regulatory factor 1 (IRF1), suggesting that a deubiquitinase is recruited during gene activation. Here, we report that RNAi-mediated knockdown of the ubiquitin hydrolase, USP22, results in 2-fold higher ubH2B, and 2-fold lower transcriptional elongation at IRF1. We also demonstrate that USP22 depletion diminishes 3'-end cleavage/polyadenylation by 2- to 3-fold. Furthermore, the polyadenylation factor CPSF73 is not effectively recruited, and serine 2 phosphorylation (Ser2P) of the C-terminal domain of RNA polymerase II is also disrupted. The transcriptional and processing defects observed in the USP22-knockdown cells are reversed by transient USP22 overexpression. Together, these results suggest that ubH2B helps recruit polyadenylation factors to STAT1-activated genes. We propose a working model, wherein a cycle of H2B ubiquitination/deubiquitination specifies Ser2P to regulate elongation and 3'-end processing of JAK-STAT-inducible mRNAs. These results further elaborate USP22 function and its role as a putative cancer stem cell marker.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22067483     DOI: 10.1096/fj.11-189498

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  17 in total

1.  A high-confidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complex.

Authors:  Sean M Armour; Eric J Bennett; Craig R Braun; Xiao-Yong Zhang; Steven B McMahon; Steven P Gygi; J Wade Harper; David A Sinclair
Journal:  Mol Cell Biol       Date:  2013-02-04       Impact factor: 4.272

2.  Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics.

Authors:  Jun Liang; Xianli Zhang; Shao Xie; Xiuping Zhou; Qiong Shi; Jinxia Hu; Weifeng Wang; Weifeng Qi; Rutong Yu
Journal:  Med Oncol       Date:  2014-02-27       Impact factor: 3.064

3.  USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.

Authors:  Randy S Schrecengost; Jeffry L Dean; Jonathan F Goodwin; Matthew J Schiewer; Mark W Urban; Timothy J Stanek; Robyn T Sussman; Jessica L Hicks; Ruth C Birbe; Rossitza A Draganova-Tacheva; Tapio Visakorpi; Angelo M DeMarzo; Steven B McMahon; Karen E Knudsen
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

4.  The many roles of the conserved eukaryotic Paf1 complex in regulating transcription, histone modifications, and disease states.

Authors:  Brett N Tomson; Karen M Arndt
Journal:  Biochim Biophys Acta       Date:  2012-09-06

5.  The epigenetic modifier ubiquitin-specific protease 22 (USP22) regulates embryonic stem cell differentiation via transcriptional repression of sex-determining region Y-box 2 (SOX2).

Authors:  Robyn T Sussman; Timothy J Stanek; Paul Esteso; John D Gearhart; Karen E Knudsen; Steven B McMahon
Journal:  J Biol Chem       Date:  2013-06-12       Impact factor: 5.157

6.  Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics.

Authors:  Meng Yang; Yun-Duo Liu; Yan-Ying Wang; Tian-Bo Liu; Ting-Ting Ge; Ge Lou
Journal:  Tumour Biol       Date:  2013-08-27

7.  Inhibition of polyadenylation reduces inflammatory gene induction.

Authors:  Alexander Kondrashov; Hedda A Meijer; Adeline Barthet-Barateig; Hannah N Parker; Asma Khurshid; Sarah Tessier; Marie Sicard; Alan J Knox; Linhua Pang; Cornelia H De Moor
Journal:  RNA       Date:  2012-11-01       Impact factor: 4.942

8.  The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs.

Authors:  Lihua Shi; Zhe Zhang; Angela M Yu; Wei Wang; Zhi Wei; Ehtisham Akhter; Kelly Maurer; Patrícia Costa Reis; Li Song; Michelle Petri; Kathleen E Sullivan
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

9.  Operative ubiquitin-specific protease 22 deubiquitination confers a more invasive phenotype to cholangiocarcinoma.

Authors:  Bo Tang; Shijie Cai; Liming Wang; Yu Tian; Chengye Wang; Yan Wang; Jiakai Mao; Yifan Yao; Zhenming Gao; Rui Liang; Mingliang Ye
Journal:  Cell Death Dis       Date:  2021-07-05       Impact factor: 8.469

10.  USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma.

Authors:  Songlin Piao; Yanlong Liu; Jing Hu; Fulin Guo; Jie Ma; Yao Sun; Bin Zhang
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.